Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech
Clinics
;
69(4): 279-293, 4/2014. tab, graf
Artículo
en Inglés
| LILACS
| ID: lil-705781
ABSTRACT
Gonadotropin therapy plays an integral role in ovarian stimulation for infertility treatments. Efforts have been made over the last century to improve gonadotropin preparations. Undoubtedly, current gonadotropins have better quality and safety profiles as well as clinical efficacy than earlier ones. A major achievement has been introducing recombinant technology in the manufacturing processes for follicle-stimulating hormone, luteinizing hormone, and human chorionic gonadotropin. Recombinant gonadotropins are purer than urine-derived gonadotropins, and incorporating vial filling by mass virtually eliminated batch-to-batch variations and enabled accurate dosing. Recombinant and fill-by-mass technologies have been the driving forces for launching of prefilled pen devices for more patient-friendly ovarian stimulation. The most recent developments include the fixed combination of follitropin alfa + lutropin alfa, long-acting FSH gonadotropin, and a new family of prefilled pen injector devices for administration of recombinant gonadotropins. The next step would be the production of orally bioactive molecules with selective follicle-stimulating hormone and luteinizing hormone activity.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Inducción de la Ovulación
/
Hormona Luteinizante
/
Hormona Folículo Estimulante
/
Gonadotropina Coriónica
Límite:
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Clinics
Asunto de la revista:
Medicina
Año:
2014
Tipo del documento:
Artículo
País de afiliación:
Brasil
Institución/País de afiliación:
Andrology & Human Reproduction Clinic (ANDROFERT)/BR
Similares
MEDLINE
...
LILACS
LIS